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in Inverse Planning
Caiping Guo, PhD1,2 , Pengcheng Zhang, PhD2, Zhiguo Gui, PhD2,
Huazhong Shu, PhD3,4, Lihong Zhai, MD1, and Jinrong Xu, MD1
Abstract
Objective: An automatic method for the optimization of importance factors was proposed to improve the efficiency of inverse
planning.Methods: The automatic method consists of 3 steps: (1) First, the importance factors are automatically and iteratively
adjusted based on our proposed penalty strategies. (2) Then, plan evaluation is performed to determine whether the obtained
plan is acceptable. (3) If not, a higher penalty is assigned to the unsatisfied objective by multiplying it by a compensation coefficient.
The optimization processes are performed alternately until an acceptable plan is obtained or the maximum iteration Nmax of step
(3) is reached. Results: Tested on 2 kinds of clinical cases and compared with manual method, the results showed that the quality
of the proposed automatic plan was comparable to, or even better than, the manual plan in terms of the dose–volume histogram
and dose distributions. Conclusions: The proposed algorithm has potential to significantly improve the efficiency of the existing
manual adjustment methods for importance factors and contributes to the development of fully automated planning. Especially,
the more the subobjective functions, the more obvious the advantage of our algorithm.
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CERR, computational environment for radiotherapy research; CI, conformity index; CT, computed tomography; DV, dose–
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homogeneity index; HN, head and neck; IMRT, intensity-modulated radiotherapy; NTs, normal tissues; NTCP, normal tissue
complication probability; OARs, organs at risk; PTV, planning target volume; TCP, tumor control probability
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Introduction
Inverse planning in intensity-modulated radiotherapy (IMRT)
aims to deliver uniform doses to the planning target volume
(PTV), while sparing damage to normal tissues (NTs) and
organs at risk (OARs). The performance of an inverse planning
system depends on the optimization engine, which handles
mutually exclusive optimization goals for different structures
and accordingly adjusts beamlet intensities using an iterative
method.1 In standard inverse planning, such a trade-off is com-
monly resolved by minimizing a therapeutic objective function,
which combines different structure-specific penalty objectives
using importance factors. Two methods are commonly used to
adjust the importance factors (weighting factors): fine-tuning
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importance factors in a manual trial-and-error fashion2,3 and
multiobjective optimization, where part of the representatives
of a Pareto surface are precomputed and then navigated.1,4-9
Between the 2 methods, the former is the most commonly used,
although it is time-consuming, because lengthymanual trial-and-
error procedures are needed to find a set of suitable importance
factors to arrive at a satisfactory balance between the PTV cov-
erage and OAR sparing. Moreover, the optimization process
becomes even more complicated and time-consuming as the
number of subobjective functions increases. To improve the effi-
ciency of inverse planning, it is desirable to have an automatic, or
a more effective, approach to determine the importance factors.
To achieve this goal, some authors have proposed schemes
to automatically adjust the importance factors. Xing et al10
proposed a method for auto-optimizing importance factors
using 2-stage optimization under the guidance of a predefined
dose–volume histogram (DVH) score function. In a similar
vein, some researchers proposed methods to automatically
optimize treatment plans guided by a reference plan.8,11-24 Of
these, the source of the reference plan, for different clinical
applications, is not the same. For automatic replanning, the
reference plan comes from a clinically delivered original plan
for the same patient. For knowledge-based approaches, the
reference plan for an incoming cancer patient is based on retro-
spective patient data. These methods can automatically adjust
the importance factors but require a prechosen DVH curve for
each optimized organ. Due to the differences and variances of
patient-specific anatomical structures, it is difficult to choose
beforehand the ideal DVH curves for both the traditional
inverse planning and replanning process. Additionally, some
investigators, using machine learning, have proposed methods
to predict OAR weights25 and OAR DVHs26-28 for some cancer
cases. Dias et al29 implemented the automatic optimization of
prescribed doses and importance factors by applying the theory
of fuzzy inference. All the aforementioned methods are based
on dose-based optimization models.
In this study, we focused on automatic optimization for IMRT
treatment planning to avoid the requirement of human planner
intervention. An effective and simple computer-aided method to
automatically and iteratively adjust the importance factors with-
out manual intervention was proposed. Moreover, compared
with the aforementioned automatic important factor optimiza-
tion methods, the advantages of our proposed method are: (1) It
does not need a reference plan, but is suitable for automatic
optimization method based on a reference plan; (2) It does not
need a large number of clinical cases to train prediction model;
(3) It does not need to design complex membership functions;
and (4) It not only applies to dose-based physical optimization,
but also to others, such as biological and hybrid optimization.
Materials and Methods
Optimization Technique
The core of the automatic method is the iterative and automatic
adjustment of importance factors based on the difference between
actual dose and the prescribed value within a certain small num-
ber of iterations. Figure 1 depicts a flow chart of the automatic
method. (1) First, the importance factors are automatically and
iteratively adjusted based on proposed penalty strategies. (2)
Then, plan evaluation is performed to determine whether the
obtained plan is acceptable according to evaluation functions.
(3) If not, a higher penalty is assigned to the unsatisfied objective
bymultiplying a compensation coefficient. The optimization pro-
cesses are performed iteratively until an acceptable plan is
obtained or the maximum iteration Nmax of step (3) is reached.
These optimization problems were solved using the limited-
memory Broyden–Fletcher–Goldfarb–Shanno gradient optimi-
zationalgorithm,30 and square roots of beamletweightswereused
as variables to avoid nonphysical solutionswith negative values.1
The following sections provide details of the automatic method.
Prescription value-based penalty strategies. In clinical practice,
prescription values mainly include minimum dose, maximum
dose, mean dose, maximum dose–volume (DV) constraints,
minimum DV constraints, generalized equivalent uniform dose
(gEUD),31 tumor control probability (TCP), and NT complica-
tion probability (NTCP).32 We use wnew and wold to, respec-
tively, denote the current importance factors and automatically
adjusted importance factors, where we defined the relationship
between them as
Figure 1. Overview of the automatic FMO. FMO indicates fluence
map optimization.
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wnew ¼ wold þ factor: ð1Þ
where factor is defined as weight correction factor which is a
function of prescription value and actual value. For different
prescription values, the factor proposed in this article is defined
in Table 1. The subscripts pre and cur represent the prescription
value and the actual value in the current plan, respectively. For
DV constraint, V1 is the prescribed volume with respect to
prescribed dose D1 and V2 the actual volume in the given plan
with respect to D1.
For example, the minimum dose criterion is typically used
to control the low dose delivered to PTV. The penalty for it is
the greater the difference between Dmincur and Dminpre, the
greater the corrector factor. Hence, a higher importance factor
is assigned to the minimum-dose-based subscore. But maxi-
mum dose criterion is typically used to constrain the overdose
delivered to PTV or OAR. The greater the maximum dose of
the current plan, the greater the factor. Other penalty strategies
are formatted similarly.
The automatic adjustment of importance factors, shown
in rectangle I in Figure 1, compromises the requirement of
PTV coverage and OARs sparing based on prescription
value-based penalty strategies. Then, plan evaluation is
performed.
Plan evaluation. Plan evaluation is performed according to 2
evaluation functions, which are provided in Equations 2 and
3, which are respectively express the PTV coverage considered
in priority, and the maximum DV objectives for OARs. N is the
number of the DV constraints.
f1 ¼ VPTVðDmin preÞ  95% ð2Þ
f2 ¼ VOARðD1iÞ  V1i% i ¼ 1   N ð3Þ
The criteria for plan evaluation are listed as follows: (1) If
the PTV coverage is satisfied, while the specific DV constraints
of OARs are not satisfied, the algorithm considers improving
the OARs DV constraints without jeopardizing the pre-
scribed PTV coverage. If the OAR doses cannot be made
to satisfy all the conditions without compromising the pre-
scribed PTV coverage, the high-dose region of the OAR
will be considered first. (2) If the PTV coverage is dissa-
tisfied, a higher penalty, imposed by multiplying by a com-
pensation coefficient, is assigned to the weight correction
factors of the subscores controlling PTV, until the dose
constraint of the PTV was satisfied. (3) If the PTV coverage
and OARs DV constraints are all satisfied, the algorithm
tries to improve the PTV coverage as far as possible while
ensuring the prescribed OARs DV constraints; if OAR doses
are needed to decrease to the fullest extent, the algorithm
can try to decrease the OAR doses as far as possible while
ensuring the prescribed PTV coverage.
Ideally, if the prescription values are well-defined, an accep-
table plan is generated only by the step in Figure 1 (rectangle I).
Otherwise, a compensation stage will be performed.
Compensation stage. During the compensation stage, the unsa-
tisfied objective is assigned a higher penalty by multiplying by
a coefficient k defined in Equation 4. Then, the fluence map
optimization (FMO) shown in rectangle I in Figure 1 is per-
formed once again. Figure 2 shows the process, k0 represents
the initial value, and steplength represents the variation of the k
between iterations.
wnew ¼ wold þ k  factor ð4Þ
Objective function. Three representative objective functions
(DV-based objective function, gEUD-based physical–biologi-
cal objective function, and NTCP-based physical–biological
Table 1.Weight Correction Factors for Different Prescription Values.
Prescription
Value Factor
Dminpre Dminpre=Dmincur
Dmaxpre Dmaxcur=Dmaxpre
Dmeanpre maxðDmeancur;DmeanpreÞ=minðDmeancur;DmeanpreÞ
for PTV
Dmeanpre Dmeancur=Dmeanpre for OAR
DVmax V2=V1
DVmin V1=V2
gEUD gEUDcur=gEUDpre; a  1 for OAR
gEUD gEUDpre=gEUDcur; a < 1 for PTV
NTCP NTCPcur=NTCPpre
TCP TCPpre=TCPcur
Abbreviations: gEUD, generalized equivalent uniform dose; NTCP, normal
tissue complication probability; OAR, organ at risk; PTV, planning target
volume; TCP, tumor control probability.
Current plan is not
acceptable
Determine the
objective needed to
be given more
penalty
Adjust the weight(s)
of unsatisfied
objective by
new oldw w k factor
0
0
k k steplength
k k
FMO using L-BFGS
= +
=
= + .
Figure 2. Process of compensation stage.
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objective function) were used in our study. The weighted sum
of objective function f to be minimized is
f ðDÞ ¼
Xl
i¼1
wi fiðDÞ; ð5Þ
where importance factor wi represents clinical significance, l
is the number of subobjective functions, and D is the dose
distributions to the organ constrained by subscore fi. To
avoid numerical errors in the automatic procedure, the
importance factors were kept within a specific range
through normalization by Equation 6. The importance fac-
tors were kept within (0, 1). It is worth noting that the
normalization does not affect the optimal solution from the
mathematical standpoint.
wi ¼ wiPl
i¼1
wi
ð6Þ
DV-based objective function. Dose–volume-based optimization is
common in clinical settings for IMRT treatment planning. The
DV-based model used in our study was
f ðDðxÞÞ ¼ w1 fMinðDPTVÞ þ w2 fMeanðDPTVÞ
þ
X5
i¼3
wi fDVmaxOAR1ðDÞ þ
X8
i¼6
wi fDVmaxOAR2ðDÞ þ   
ð7Þ
Due to the nonconvexity of the DV criterion,33 the equiva-
lent convex DV criterion was used to construct the maximum
DV subscore.34 The subscores used in DV-based optimization
model are expressed as follows:
fMinðDÞ ¼ 1
N
XN
i¼1
HðDMin DiÞ  ðDMin DiÞ2; ð8Þ
fMeanðDÞ ¼ 1
N
XN
i¼1
ðDi  DMeanÞ2 ; ð9Þ
fDVmaxðDÞ ¼
1
N
XN
i¼1
HðDi  D1Þ  HðD2 DiÞ  ðDi  D1Þ2 ;
ð10Þ
where H(x) represents the step function; Di is the dose in the ith
voxel; N is the number of voxels in PTV or OAR; the maximum
DV constraint VD1  V1% indicates that the volume of the
OAR receiving dose greater than D1 should be less than
V1%, D2 is in the current plan, where VD2 ¼ V1%.
gEUD-based physical–biological objective function. The advantages
of gEUD-based optimization have been widely investi-
gated.3,6,34-41 Previous studies have shown the superiority
of gEUD-based physical–biological optimization compared
with gEUD-based biological optimization.37,40 Based on
their findings, the gEUD-based objective function used in
our work was,
f ðDÞ ¼ w1 fMinðDPTVÞ þ w2 fMeanðDPTVÞ þ
XNOAR
i¼1
wiþ2 fgEUDðDÞ;
ð11Þ
where
fgEUDðDÞ ¼ HðgEUDcurðDÞ  gEUDpreÞ  ðgEUDcurðDÞ  gEUDpreÞ;
ð12Þ
NOAR is the number of OARs; gEUD is given by Nie-
mieko,31 the wi is given from Equation 6.
NTCP-based physical–biological objective function. NTCP-based
optimization has been investigated in inverse treatment plan-
ning42-46 and incorporated into some commercial treatment
planning software.44,47 The NTCP-based objective function
was expressed in Equation 13. The NTCP model used here was
the LKB model.48,49
f ðDÞ ¼ w1 fMinðDPTVÞ þ w2 fMeanðDPTVÞ þ
XNOAR
i¼1
oiþ2 fNTCPðDÞ:
ð13Þ
To use a gradient-based optimization algorithm to solve the
nonconvex NTCP-based optimization problem, the following
equivalent convex NTCP criterion38 was applied. The NTCP-
based subscore50 utilized in our work was defined in
Equation.14
fNTCPðDÞ ¼ maxðlnð1 NTCPpreÞ  lnð1 NTCPLKBðDÞ; 0Þ
ð14Þ
Patients, Related Parameters, and Assessment Criteria
The feasibility and performance of the automatic method was
tested on 10 cases of prostate cancer and 3 cases of head and
neck (HN) cancer randomly selected from the database of
treated cases. The study protocols were approved by the Ethics
Committee of the North University of China with the approval
No. 2018006, the written consent forms were signed by the
participants whose computed tomography (CT) images were
used for this study.
For prostate cancer cases, these patients underwent simula-
tion and treatment in the supine position. Target volume and
OARs (bladder, rectum, and femoral heads) were delineated on
CT slices. The rectum and bladder walls were generated with a
thickness of 5 mm from the external manually delineated rectal
and bladder contours, respectively. A “tissue ring,” the outside
of the area extending the PTV by 5 cm, was defined as the other
NT. The target volume included the prostate and excluded the
pelvic lymph nodes. The PTV was calculated by adding a 10
mmmargin in all directions except the posterior, where a 5 mm
margin was applied. All plans used the identical configuration
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of 5 coplanar 6 MV photon beams, with gantry angles of 36,
100, 180, 260, and 324. The values of D1 and V1 for the
DV-based optimization are listed in Table 2. The prescribed
Dmin-pre and Dmean-pre for PTV were 74 Gy and 78 Gy, respec-
tively. The prescribed gEUDpre and NTCPpre for rectum and
bladder were 60 Gy and 0.05, respectively. The NTCP and
gEUD radiobiological parameters for the bladder and rectum
were taken from studies, respectively.51,52
For HN cancer cases, patients, related optimization para-
meters applied in Equations 7 and 11, and plan assessment
criteria are same as those in our previous study.53 The pre-
scribed NTCPpre for OARs (spinal cord, brainstem, L-parotid,
and R-parotid) was 0.1.
The number of maximum iterations was 5 in rectangle I in
Figure 1, empirically chosen through a series of experiments.
The dose sedimentary matrix was calculated with a standard
pencil beam algorithm,54 implemented on the computational
environment for radiotherapy research (CERR).55 All experi-
ments were performed by using an instrument equipped with a
32-bit OS, Windows 7, and an Intel (R) Core (TM) i3-4150
CPU with 4G RAM.
The plan quality was assessed by using the clinical evalua-
tion guidelines shown in Table 3.56 Conformity index (CI) and
homogeneity index (HI)57 are, respectively, defined in Equa-
tions 15 and 16.
CI ¼Vt;ref
Vt
Vt;ref
Vref
; ð15Þ
where Vt is the volume of the PTV, Vt;ref is the target volume
that receives a dose greater than or equal to the reference (pre-
scribed) dose, and Vref is the total volume that receives a dose
greater than or equal to the reference dose.
HI ¼ D5%
D95%
; ð16Þ
where D5% and D95% correspond to the minimum doses deliv-
ered to the hottest 5% and 95% of the PTV, respectively.
All statistical tests were performed using the Wilcoxon
matched-pair, signed-rank test using a significance level of
0.05.
Table 2. D1 and V1 for the DV Subobjective Functions.
OAR D1 (Gy) V1 (%)
Rectum 50 40
65 25
75 15
Bladder 65 35
70 30
75 16
Abbreviations: DV, dose–volume; OAR, organ at risk.
Table 3. Dose–Volume Criteria for Bladder and Rectum.
OAR Parameters of DV constraints
Bladder V65 < 50% V70 < 35% V75 < 25% V80 < 15%
Rectum V50 < 50% V60 < 35% V65 < 25% V70 < 20% V75 < 15%
Abbreviations: DV, dose–volume; OAR, organ at risk.
Table 4. Optimized Compensation Coefficient k for 3 Optimization Methods.
Case
DV-Based gEUD-Based NTCP-Based
wPTV
inew
¼ wPTViold þk  factor
i ¼ 1, 2 in Equation 7
wPTV
inew
¼ wPTViold þ k  factor
i ¼ 1, 2 in Equation 11
winew ¼ wiold þ k  factor for rectum
and parotids i for rectum
Prostate 1 1 10 4
Prostate 2 10 30 1
Prostate 3 1 10 2
Prostate 4 8 20 1
Prostate 5 9 20 1
Prostate 6 3 20 4
Prostate 7 1 25 1
Prostate 8 1 25 1
Prostate 9 8 20 4
Prostate 10 10 15 2
HN 1 5 10 2
HN 2 2 20 1
HN 3 8 25 3
Abbreviations: DV, dose–volume; gEUD, generalized equivalent uniform dose; HN, head and neck; NTCP, normal tissue complication probability.
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It should be pointed out that the differences of the DVH
criteria for the bladder and rectum in Tables 2 and 3 are that
the DVH criteria in Table 2 are prescribed DV constraints in
Equation 10, while the DVH criteria in Table 3 are evaluation
guidelines to determine whether optimized plan is clinically
accepted. For different prostate patients, the evaluation guide-
lines are same, but the prescribed DV constraints should be
tightened and relaxed depending on the patients’ different
structures.
Results
In Optimization Technique section, we proposed an automatic
algorithm for dynamically generated acceptable importance
factors for IMRT inverse treatment planning. Next, we
describes an investigation of the automatic method.
Determination of Iteration Number
First, we investigated the impact of iteration numbers on the
convergence of the algorithm and plan quality. It was found
that the total iteration number to be 15, which is always enough
to get an acceptable plan based on our a series of experiments.
Then by using different combinations of iteration numbers of
iterative adjustment shown in rectangle I in Figure 1 and com-
pensation stage shown in rectangle II in Figure 1, we found that
by performing compensation stage, the algorithm can further
improve the plan quality than only by performing iterative
adjustment shown in rectangle I in Figure 1. But after each
adjustment of the compensation coefficient, because of the
repetitive performing of iterative adjustment shown in rectan-
gle I in Figure 1, the computation time becomes longer. As this
test was consistent for different cases, we fixed the number of
iterations at 5 in rectangle I in Figure 1 and the maximum
iteration was 10 in rectangle II in Figure 1, which allows the
algorithm to show the trade-off between the gain in plan quality
and the cost in computation time.
Effects of Compensation Coefficient
Under the above-prescription values, Table 4 lists the optimized
compensation coefficient k for testing cases in 3 kinds of opti-
mization methods. It was observed that in the DV-based optimi-
zation and gEUD-based optimization, the weight correction
factors of subscores for PTV needed to be given extra penalty
by multiplying a compensation coefficient, whereas in the
NTCP-based optimization, the subscore for rectum or parotids
needed to be given extra penalty; k0 for the DV-based, gEUD-
based, and NTCP-based optimizations were, respectively, 1, 10,
and 1. The respective step lengths were 1, 5, and 1.
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Figure 3. Dose–volume histograms of gEUD plans with different
coefficient k for patient 2. gEUD indicates generalized equivalent
uniform dose.
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Figure 4. Dose–volume histograms of the NTCP plan with k ¼ 1 and
k ¼ 2 for patient 8. A, full DVH curves; (B) high-dose region of the
DVH curves. Blue curves for PTV, red curves for rectum, and green
curves for bladder. DVH indicates dose–volume histogram; NTCP,
normal tissue complication probability; PTV, planning target volume.
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Table 5. Dose Conformity and Homogeneity to the PTV of the Automatic Plan for 10 Prostate Cases.
Index Method
Prostate HN (PTV70, PTV63, PTV56)
1 2 3 4 5 6 7 8 9 10 1 2 3
DV-based 0.88 0.87 0.90 0.88 0.90 0.85 0.85 0.85 0.86 0.86 0.84 0.59 0.48 0.89 0.53 0.36 0.80 0.45 0.25
CI gEUD-based 0.88 0.87 0.90 0.87 0.90 0.86 0.85 0.86 0.85 0.86 0.83 0.60 0.49 0.86 0.50 0.35 0.78 0.44 0.29
NTCP-based 0.88 0.87 0.90 0.87 0.89 0.85 0.85 0.84 0.87 0.86 0.84 0.67 0.41 0.88 0.51 0.36 0.78 0.42 0.27
DV-based 1.02 1.02 1.04 1.02 1.06 1.03 1.02 1.02 1.05 1.02 1.04 1.08 1.06 1.07 1.09 1.05 1.05 1.10 1.10
HI gEUD-based 1.02 1.02 1.04 1.02 1.06 1.04 1.02 1.02 1.04 1.02 1.08 1.10 1.08 1.09 1.10 1.06 1.05 1.13 1.10
NTCP-based 1.02 1.02 1.04 1.02 1.06 1.02 1.02 1.01 1.02 1.02 1.07 1.09 1.06 1.08 1.13 1.08 1.07 1.15 1.11
Abbreviations: CI, conformity index; DV, dose–volume; gEUD, generalized equivalent uniform dose; HI, homogeneity index; NTCP, normal tissue complication
probability; PTV, planning target volume.
A B
C
Figure 5. Comparisons of DV criteria for DV plan. DV indicates dose–volume. A, Dose comparison of PTV-95% for DV plan; (B) DVH
comparison of Bladder for DV plan(“*”:B-65Gy,“e”: B-70Gy,“o”: B-75Gy); (C) DVH comparison of Rectum for DV plan(“*”:R-60Gy,“e”:
R-65Gy,“o”: R-75Gy).
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Figure 3 shows the evolutionary process of the gEUD-based
optimization with different compensation coefficient k for
prostate patient 2. It can be seen that the greater the important
factors with higher coefficient k for the PTV subscores, the
greater the dose coverage within the target, whereas OARs
sparing decreased because of the trade-off.
If we want to further improve the quality of the automatic
plan for a specific objective, we can manually impose a com-
pensation coefficient on the objective. Taking the optimized
DV plan of prostate patient 8 for example, Figure 4 shows the
difference between the plans with k¼ 1 and k¼ 2. The aim is to
further improve the dose distribution of PTV with k ¼ 2 yield-
ing improved PTV coverage. The same approach can be used to
improve other objectives.
Plan Comparison
For the automatic plans, PTV coverage quantified by CI and HI
is guaranteed for testing cases in 3 kinds of optimization meth-
ods (Table 5). It is clear that the proposed automatic method
yields good dose conformity and homogeneity to the PTV.
Next, the automatic plan was compared with the manual
plan generated in CERR by experienced physicians and
reported in other literature created by our team members.50 For
prostate cancer cases, Figures 5–7 present the comparative
results corresponding to DVH criteria for the PTV and OARs.
The data labeled PTV-95% represent the volume fraction of the
PTV receiving 0.95  78 Gy of radiation. The other labels are
formatted similarly, where the acronyms correspond to the
bladder (B) and rectum (R). The black scatter point represents
A B
C
Figure 6. Comparisons of DV criteria for gEUD plan. DV indicates dose–volume; gEUD, generalized equivalent uniform dose. A, Dose
comparison of PTV-95% for gEUD plan; (B) DVH comparison of Bladder for gEUD plan(“*”:B-65Gy,“e”: B-70Gy,“o”: B-75Gy); (C) DVH
comparison of Rectum for gEUD plan(“*”:R-60Gy,“e”: R-65Gy,“o”: R-75Gy).
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the result of the automatic plan, and the grey scatter point
represents the result of the manual plan. The comparative
results demonstrate that the automatic method can generated
clinically acceptable plans in terms of PTV coverage and
OARs sparing. Moreover, the comparisons in Figures 5–7 indi-
cate that the quality of the automatic plan is better than that of
manual plan considering DV constraints. For example, the
automatic DV plan for patient 5 in Figure 5 yields better PTV
coverage and better trade-off between bladder-sparing and
rectum-sparing compared to manual DV plan. The same con-
clusion can be applied to the other plan comparison for all
testing cases.
Figure 8A-C present the comparative DVHs between the
automatic plans and the manual plans based on DV model,
gEUD model, and NTCP model for patient 1. The red
curves present the automatic plan, and the blue curves pres-
ent the manual plan. The acronyms “A” and “M” correspond
to the automatic method and the manual method. The com-
parison of DVHs demonstrates that our proposed automatic
method can result in better trade-off between PTV coverage
and OARs sparing.
For HN cases, the same comparisons were performed.
Figure 9 compares the average DVHs for the automatic DV
plan and the DV manual plan. It clearly shows improvement
for all OARs. Similarly, comparisons corresponding to DVH
criteria for the PTVs and OARs were also performed. The
comparative results indicate that the automatic plans are better
than that of manual plan in terms of OARs protection.
A B
C
Figure 7. Comparisons of DV criteria for NTCP plan. DV indicates dose–volume; NTCP, normal tissue complication probability. A, Dose
comparison of PTV-95% for NTCP plan; (B) DVH comparison of Bladder for NTCP plan(“*”:B-65Gy,“e”: B-70Gy,“o”: B-75Gy); (C) DVH
comparison of Rectum for NTCP plan(“*”:R-60Gy,“e”: R-65Gy,“o”: R-75Gy).
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To further prove the efficiency of our proposed automatic
method, we also considered spatial dose information. Consistent
with the comparison of the DVHs, the automatic plans retained
similar or better dose distributions compared to the manual plan.
Statistical Analysis of Experimental Results
To compare the results between the automatic plan and the
manual plan for all testing cases, the statistically analysis were
performed. There are no significant differences in CI and HI
that indicate the similar dose coverage to the PTVs between 2
kinds of plans. As shown in Figures 5–7, for 10 prostate cancer
cases, no significant difference was found between these DV
values for automatic plan and manual plan in 3 kinds of opti-
mization methods. For 3 cases with HN cancer, the Wilcoxon
test was performed for the difference dose bins of DVH in
Figure 9, significant differences were observed for the Dmean
to the cord and the brainstem.
Changes of Importance Factors
To illustrate the variances of the importance factors in auto-
matic method, taking gEUD-based optimization as an example
for patient 6 with prostate cancer, Figure 10 shows the var-
iances with respect to iterations. In the optimization of all other
cases, the weight changes were similar.
Influence of Initial Importance Factors
The proposed algorithm is intended to be automatic optimiza-
tion for importance factors, so we would not like to have the
planner initializing the importance factors by trial and error. In
our experiments, we used uniform initial importance factors.
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Figure 8. Dose–volume histograms for patient 1. A, Comparison between manual DV plan (M-DV) and automatic DV plan (A-DV); (B)
comparison between manual gEUD plan (M-gEUD) and automatic gEUD plan (A-gEUD); (C) comparison between manual NTCP plan
(M-NTCP) and automatic NTCP plan (A-NTCP). DV indicates dose–volume; gEUD, generalized equivalent uniform dose; NTCP, normal
tissue complication probability.
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For example, the uniform initial weights (1/4, 1/4, 1/4, 1/4)
were used in gEUD-based optimization. We then tested the
stability performance of the automatic method using different
sets of initial importance factors generated randomly and found
that different initial importance factors will only have as a
consequence a decrease or an increase in the total computation
time and not in the quality of the final plan.
Influence of Prescribed Value
A series of experiments showed that whether the compensation
step was needed correlated to the prescribed value. The value
of the compensation coefficient k was different when optimiza-
tion was guided by different prescribed values for the same
case. This contributed to the fact that different prescribed
values led to different penalties. We found that for the testing
cases, the choice of prescription value only resulted in different
values of k and not in the quality of the optimized treatment
plan. Still, it should be pointed out that if the prescription
values cannot result in acceptable plan within limited itera-
tions, physicians manually adjust them according to their expe-
rience, and then repeat the automatic method.
Discussions and Conclusions
In this article, we proposed a prescription value-based auto-
matic importance factor optimization algorithm that avoids
tedious manual trial-and-error schemes of the traditional man-
ual method. Furthermore, this advantage becomes more and
more apparent with increase in the number of subobjective
functions. It should be pointed out that our proposed prescrip-
tion value-based penalties strategies shown in Table 1 are novel
and the compensation coefficient introduced in our algorithm
can improve the flexibility of the new automatic method. More-
over, different initial importance factors have minimal impact
on the plan quality. In our experiments, for different prostate
cases and HN cases, it takes 3 to 7 minutes or 5 to 11 minutes to
produce an acceptable plan applying our proposed automatic
optimization method of importance factors, while for manual
trial-and-error method, it needs experienced physicians to take
1 to 3 hours to obtained an acceptable plan. The substantial
reduction in human intervention will greatly improve the effi-
ciency of radiotherapy. The automatic optimization of impor-
tance factors runs without any interaction, leaving the
dosimetrists free for other tasks, and minimizes the time spent
on the whole process. The complexity of the patient anatomy,
the number of loops executed by the algorithm, and the amount
of importance factors put on the cost functions will also influ-
ence the calculation time.
It should be pointed out that our main purpose is to describe
a new and simple method of adjusting importance factors in an
automatic way based on prescription value, not for dose com-
parison with other existing methods because of their intrinsic
differences, while in the near future, we will actively carry out
the corresponding comparative work to further prove the effi-
ciency of our proposed method. Moreover, different from the
other automatic method, our proposed method can be applied
not only to dose-based optimization, but also to other optimiza-
tion models, such as NTCP-based or TCP-based optimization.
In other automatic optimization methods, dose-based models
were only used.
There persist challenges and room for improvement in this
vein. First, the manner in which we adjust the compensation
coefficient k, mentioned in Optimization Technique section,
remains heuristic, due to the uncertain relationship between
DVH curves and importance factors. This relationship needs
to be further investigated for an efficient way to adjust k.
Second, while the prostate and HN are partial tumor sites,
there is potential for expanding this automatic technique to
other tumor sites. Finally, we only study the automatic opti-
mization of weighting factors of the FMO omitting the
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segmentation of beamlet intensity. In future study, we need to
include automatic segmentation of beamlet intensity into the
automatic optimization process while keeping the quality of
the fluence-optimized dose distribution during segmentation
to achieve the real fully automatic optimization. Nevertheless,
the proposed method does find importance factors using a
reasonably simple method, which was shown in this article.
The automatic treatment plan can serve as a reference plan
and starting point for the specific treatment and, at least,
ensure a certain minimum quality.
Finally, the proposed automatic method can not only be
used in inverse treatment planning in IMRT, but can also auto-
matically generate volumetric modulated arc therapy plans.
Related work is in progress.
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